Lyme Disease Testing: Types, Accuracy, and When to Get Tested
At a Glance
- The standard two-tier testing protocol (ELISA followed by Western Blot) misses up to 60% of early Lyme cases
- Testing too early after a tick bite often produces false negatives because antibodies take 2 to 6 weeks to develop
- Specialty labs like iGeneX use expanded testing panels that may catch cases standard labs miss
- PCR testing detects Borrelia DNA directly but works best on joint fluid, not blood
- A clinical diagnosis based on symptoms and exposure history remains essential, especially in early Lyme
If you suspect Lyme disease, getting the right test at the right time can mean the difference between a quick recovery and months (or years) of unexplained symptoms. The problem? Lyme testing is far from perfect. The standard tests miss a significant number of cases, and the timing of when you test matters enormously.
This guide walks you through every major Lyme disease test available today, explains what the results actually mean, and helps you understand when standard testing falls short.
How the Standard Two-Tier Testing Protocol Works
The CDC recommends a two-step process for diagnosing Lyme disease. First, your doctor orders an ELISA (enzyme-linked immunosorbent assay) test. If that comes back positive or equivocal, a Western Blot test is run to confirm the result.
The logic sounds reasonable: use a sensitive screening test first, then confirm with a more specific test. In practice, this system has serious gaps that every patient should understand.
Step 1: The ELISA Test
The ELISA measures antibodies your immune system produces in response to Borrelia burgdorferi, the bacterium that causes Lyme disease. A blood sample is mixed with Lyme antigens. If your blood contains antibodies against Borrelia, they bind to these antigens and produce a measurable color change.
The ELISA is designed to be highly sensitive, meaning it should catch most true positives. The trade-off is that it also produces false positives from cross-reactivity with other infections (EBV, syphilis, autoimmune conditions). That is why a positive ELISA alone is not considered diagnostic.
Step 2: The Western Blot
If your ELISA is positive or borderline, the Western Blot test separates Borrelia proteins by size and checks which specific antibody “bands” your immune system reacts to. The CDC requires reactivity to a set number of bands for a positive result:
- IgM Western Blot: At least 2 of 3 specific bands (23, 39, 41 kDa) within the first 30 days of infection
- IgG Western Blot: At least 5 of 10 specific bands for infections lasting longer than 30 days
This strict band requirement is where many patients fall through the cracks. You might react to 4 out of 10 IgG bands, all highly specific to Borrelia, and still receive a “negative” result by CDC standards.
The False Negative Problem
This is the single biggest issue with Lyme testing, and it trips up both patients and doctors. Multiple studies show that the two-tier protocol has a sensitivity of only 29% to 40% in early localized Lyme disease. That means it misses 60% to 70% of people who actually have early Lyme.
Why False Negatives Happen
- Testing too early. Your immune system needs 2 to 6 weeks to produce detectable antibodies. Testing during the first week or two after a bite will almost always come back negative, even if you are infected.
- Antibiotic use. If you start antibiotics early (which is the right clinical decision), they can blunt your immune response and reduce antibody production, leading to a negative test.
- Immune suppression. Patients with weakened immune systems may not produce enough antibodies to trigger a positive result.
- Borrelia strain variation. The standard tests are optimized for B. burgdorferi sensu stricto. Other pathogenic Borrelia species may not trigger the same antibody patterns.
Sensitivity improves significantly in later-stage Lyme disease, reaching 70% to 100% for patients with Lyme arthritis or neurological Lyme. But by that point, the infection has had weeks or months to cause damage that earlier treatment could have prevented.
PCR Testing: Detecting Borrelia DNA Directly
Unlike antibody-based tests, PCR (polymerase chain reaction) testing looks for Borrelia DNA itself. This is a direct detection method. If Borrelia genetic material is present in your sample, PCR can amplify it to detectable levels.
PCR has a major advantage: it does not depend on your immune response. You do not need to wait weeks for antibodies to build up. It can also identify the specific Borrelia species involved.
The downside is that Borrelia spirochetes do not circulate freely in blood for very long. They burrow into tissues quickly. This means PCR testing on blood samples has low sensitivity (often below 30%). Where PCR shines is in testing synovial (joint) fluid from patients with Lyme arthritis, where sensitivity can exceed 70%, and in cerebrospinal fluid for neurological Lyme.
Specialty Labs and Expanded Testing
Several laboratories offer testing panels that go beyond the standard two-tier approach. These labs have become particularly important for patients whose clinical picture strongly suggests Lyme but whose standard tests come back negative.
iGeneX
iGeneX in Milpitas, California, is the most well-known specialty Lyme lab. Their ImmunoBlot test uses more Borrelia antigens than standard Western Blot panels, including antigens from multiple Borrelia species. They also report “indeterminate” bands that standard labs ignore entirely.
iGeneX testing has drawn criticism from some infectious disease specialists who argue it produces too many false positives. Proponents counter that it simply catches cases the standard protocol misses. The reality likely falls somewhere in between: iGeneX testing is more sensitive but potentially less specific. It should be interpreted in clinical context, not used as a standalone diagnostic.
Other Specialty Testing Options
Vibrant Wellness Tickborne Panel: Tests for multiple tick-borne infections simultaneously and includes both antibody and antigen detection.
Galaxy Diagnostics: Specializes in Bartonella testing but also offers Borrelia panels using enrichment culture methods.
ArminLabs (Germany): Offers EliSpot and CD57 testing that measures T-cell responses to Borrelia, providing a different angle than antibody-only tests.
Comparing Lyme Disease Tests
| Test | What It Measures | Best Timing | Sensitivity (Early/Late) | Key Limitation |
|---|---|---|---|---|
| ELISA | Total antibodies to Borrelia | 4+ weeks post-bite | 40-70% / 90-100% | High false negative rate early; cross-reactivity |
| Western Blot (IgM) | Specific antibody bands | 2-4 weeks post-bite | 30-40% / Not used after 30 days | Strict band criteria miss borderline cases |
| Western Blot (IgG) | Specific antibody bands | 6+ weeks post-bite | Low / 70-100% | Takes weeks to turn positive |
| PCR (blood) | Borrelia DNA | First 2 weeks | Under 30% / Under 30% | Spirochetes leave blood quickly |
| PCR (joint fluid) | Borrelia DNA | During active arthritis | N/A / 60-80% | Requires joint aspiration |
| iGeneX ImmunoBlot | Expanded antibody panel | 4+ weeks post-bite | Higher than standard / High | May overcall some positives |
| EliSpot (T-cell) | T-cell reactivity | Any time | Variable / Variable | Not widely validated in the US |
When Should You Get Tested?
The timing of your test depends on your situation:
You found a tick and removed it. Do not rush to get tested the next day. Antibody tests will almost certainly be negative. Wait at least 2 to 3 weeks before testing. If you develop a rash (especially an expanding bull’s-eye rash), your doctor should treat you clinically without waiting for test results. The rash alone is diagnostic.
You have a bull’s-eye (erythema migrans) rash. No testing needed. This rash is considered diagnostic of Lyme disease. Treatment should begin immediately. Testing at this stage often produces false negatives and can delay treatment that should already be underway.
You have unexplained symptoms weeks after possible tick exposure. This is the ideal window for two-tier testing. Antibodies should be detectable by 4 to 6 weeks post-infection. Symptoms like fatigue, joint pain, headaches, and cognitive fog in someone who lives in or has visited a Lyme-endemic area should prompt testing.
You have chronic unexplained symptoms. If you have been dealing with fatigue, pain, neurological symptoms, or other issues for months or years, and no other diagnosis explains them, Lyme testing is reasonable. Consider specialty lab testing if standard tests are negative but clinical suspicion remains high.
Understanding Your Test Results
Test results can be confusing, especially when different labs report them differently. Here is what the common scenarios mean:
ELISA negative: By CDC protocol, testing stops here. No Western Blot is performed. This does not rule out Lyme, especially if tested early or if you are immunocompromised.
ELISA positive, Western Blot negative: Officially negative for Lyme by two-tier criteria. This could represent a false positive ELISA (from cross-reactivity) or a false negative Western Blot (antibodies present but not meeting the strict band count). Clinical judgment is needed.
ELISA positive, Western Blot positive: Confirms Lyme disease exposure. Note that antibodies can persist for months or years after successful treatment, so a positive test does not necessarily mean active infection in someone who has been previously treated.
IgM positive only (beyond 30 days): The CDC considers IgM results unreliable after 30 days of illness because false positives increase over time. However, some Lyme-literate physicians interpret a positive IgM differently, particularly if specific bands like the 23 kDa (OspC) and 39 kDa bands are reactive.
The Role of Clinical Diagnosis
Given the limitations of current testing, Lyme disease should never be diagnosed or ruled out by blood work alone. A skilled clinician considers:
- Your symptom pattern and timeline
- Tick exposure history and geographic risk
- Physical exam findings
- Response to treatment (sometimes a trial of antibiotics is both diagnostic and therapeutic)
- Laboratory results as one piece of a larger puzzle
The International Lyme and Associated Diseases Society (ILADS) emphasizes that Lyme disease is a clinical diagnosis supported by testing, not a test-dependent diagnosis. This is especially true in early Lyme, where treatment should not be delayed while waiting for antibodies to develop.
Newer Testing Approaches on the Horizon
Researchers are working on several next-generation tests that may eventually replace the two-tier protocol:
- Modified two-tier testing (MTTT): Uses two ELISA tests instead of ELISA plus Western Blot. Early studies suggest improved sensitivity in early Lyme without sacrificing specificity.
- Metabolomics-based tests: Analyze patterns of metabolites in blood that change during Borrelia infection. Could potentially detect infection before antibodies appear.
- Direct antigen detection: New technologies aim to detect Borrelia proteins (like OspA) shed into blood or urine, bypassing the need for an immune response entirely.
- T-cell based assays: Measure cellular immune responses rather than antibodies, potentially offering a more accurate picture of active infection.
None of these have replaced the current standard yet, but they represent promising directions. The FDA approved the modified two-tier approach in 2019 as an acceptable alternative, and some labs have already adopted it.
